GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Alphatec Holdings Inc (NAS:ATEC) » Definitions » ROE %

ATEC (Alphatec Holdings) ROE % : -2,012.37% (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Alphatec Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Alphatec Holdings's annualized net income for the quarter that ended in Sep. 2024 was $-158.5 Mil. Alphatec Holdings's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $7.9 Mil. Therefore, Alphatec Holdings's annualized ROE % for the quarter that ended in Sep. 2024 was -2,012.37%.

The historical rank and industry rank for Alphatec Holdings's ROE % or its related term are showing as below:

ATEC' s ROE % Range Over the Past 10 Years
Min: -1019.24   Med: -186.27   Max: -8.04
Current: -1019.24

During the past 13 years, Alphatec Holdings's highest ROE % was -8.04%. The lowest was -1,019.24%. And the median was -186.27%.

ATEC's ROE % is ranked worse than
99.13% of 802 companies
in the Medical Devices & Instruments industry
Industry Median: -0.21 vs ATEC: -1019.24

Alphatec Holdings ROE % Historical Data

The historical data trend for Alphatec Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphatec Holdings ROE % Chart

Alphatec Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -186.27 -91.05 -136.68 -676.09 -859.11

Alphatec Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1,156.31 -335.41 -595.36 -2,012.37

Competitive Comparison of Alphatec Holdings's ROE %

For the Medical Devices subindustry, Alphatec Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphatec Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Alphatec Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Alphatec Holdings's ROE % falls into.



Alphatec Holdings ROE % Calculation

Alphatec Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-186.638/( (-34.667+78.116)/ 2 )
=-186.638/21.7245
=-859.11 %

Alphatec Holdings's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-158.464/( (17.111+-1.362)/ 2 )
=-158.464/7.8745
=-2,012.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Alphatec Holdings  (NAS:ATEC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-158.464/7.8745
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-158.464 / 602.876)*(602.876 / 757.2405)*(757.2405 / 7.8745)
=Net Margin %*Asset Turnover*Equity Multiplier
=-26.28 %*0.7961*96.1636
=ROA %*Equity Multiplier
=-20.92 %*96.1636
=-2,012.37 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-158.464/7.8745
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-158.464 / -158.608) * (-158.608 / -122.704) * (-122.704 / 602.876) * (602.876 / 757.2405) * (757.2405 / 7.8745)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9991 * 1.2926 * -20.35 % * 0.7961 * 96.1636
=-2,012.37 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Alphatec Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Alphatec Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphatec Holdings Business Description

Traded in Other Exchanges
Address
1950 Camino Vida Roble, Carlsbad, CA, USA, 92008
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Executives
Patrick Miles director, officer: Executive Chairman 7475 LUSK BLVD., SAN DIEGO CA 92121
Evan Bakst director 225 CENTRAL PARK WEST, APT. 1605, NEW YORK NY 10024
David R Pelizzon director, 10 percent owner 2850 FRONTIER DR, WARSAW IN 46582
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Tyson Eliot Marshall officer: GENERAL COUNSEL & CORP. SEC. 10680 TREENA STREET, SUITE 500, SAN DIEGO CA 92131
John Todd Koning officer: Chief Financial Officer C/O MASIMO CORPORATION, 52 DISCOVERY, IRVINE CA 92618
Quentin S. Blackford director 7475 LUSK BLVD., SAN DIEGO CA 92121
David Sponsel officer: EVP, Sales C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
Scott Lish officer: SVP, Development C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
Craig E Hunsaker officer: See Remarks C/O ALPHATEC HOLDINGS, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
David H Mowry director 9775 TOLEDO, IRVINE CA 92618
Jennifer N. Pritzker 10 percent owner C/O SQUADRON CAPITAL LLC, 104 S. MICHIGAN AVENUE, SUITE 500, CHICAGO IL 60603
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Paul Segal 10 percent owner 1700 BROADWAY, 35TH FLOOR, NEW YORK NY 10019